Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TJAOA103 for Genitourinary Syndrome of Menopause
NCT07160127Phase 1Not yet recruiting
- Sponsor
- Tongji Hospital
- Start
- Sep 2025
- Primary completion
- Jun 2027
- Modality
- TCM (Traditional Chinese Medicine), HM (Herbal Medicine)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TJAOA103 in genitourinary syndrome of menopause (GSM), sponsored by Tongji Hospital. Primary endpoint: Severity of the Most Bothersome Symptom at 12 weeks. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
TJAOA103
03
Conditions
genitourinary syndrome of menopause (GSM)
Beyond the preview
Go deeper on NCT07160127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07160127.